Srdan Verstovsek

Srdan Verstovsek

UNVERIFIED PROFILE

Are you Srdan Verstovsek?   Register this Author

Register author
Srdan Verstovsek

Srdan Verstovsek

Publications by authors named "Srdan Verstovsek"

Are you Srdan Verstovsek?   Register this Author

100Publications

3065Reads

31Profile Views

Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.

Acta Haematol 2019 21;141(1):23-27. Epub 2018 Nov 21.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494427DOI Listing
September 2019

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.

PLoS One 2019 30;14(9):e0222912. Epub 2019 Sep 30.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222912PLOS
September 2019

The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Curr Hematol Malig Rep 2019 Aug;14(4):310-327

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00527-7DOI Listing
August 2019

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Curr Hematol Malig Rep 2019 Aug 1. Epub 2019 Aug 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-019-00538-4
Publisher Site
http://dx.doi.org/10.1007/s11899-019-00538-4DOI Listing
August 2019

Updates in the management of polycythemia vera and essential thrombocythemia.

Ther Adv Hematol 2019 30;10:2040620719870052. Epub 2019 Aug 30.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719870052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719465PMC
August 2019

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.

Ann Hematol 2019 Jul 15;98(7):1611-1616. Epub 2019 May 15.

Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1468, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03708-9DOI Listing
July 2019

Emerging drugs for essential thrombocythemia.

Expert Opin Emerg Drugs 2019 Jun 14;24(2):93-105. Epub 2019 May 14.

a MD Anderson Cancer Center , The University of Texas , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2019.1615437DOI Listing
June 2019

The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.

Clin Adv Hematol Oncol 2019 May;17(5):299-307

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
May 2019

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.

Br J Haematol 2019 Apr 3;185(2):382-386. Epub 2018 Aug 3.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15528
Publisher Site
http://dx.doi.org/10.1111/bjh.15528DOI Listing
April 2019

SMAC mimetics as potential cancer therapeutics in myeloid malignancies.

Br J Haematol 2019 Apr 5;185(2):219-231. Epub 2019 Mar 5.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15829DOI Listing
April 2019

SOHO State of the Art Updates and Next Questions: Myelofibrosis.

Clin Lymphoma Myeloma Leuk 2019 Apr 22;19(4):191-199. Epub 2019 Mar 22.

University of Michigan Rogel Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650193017
Publisher Site
http://dx.doi.org/10.1016/j.clml.2019.03.011DOI Listing
April 2019

Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.

Hum Pathol 2019 Mar 15;85:290-298. Epub 2018 Nov 15.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.10.026DOI Listing
March 2019

Renal complications of primary myelofibrosis.

Leuk Lymphoma 2019 Feb 3;60(2):507-510. Epub 2018 Jul 3.

f Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1474525DOI Listing
February 2019

New Concepts of Treatment for Patients with Myelofibrosis.

Curr Treat Options Oncol 2019 Jan 24;20(1). Epub 2019 Jan 24.

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0604-yDOI Listing
January 2019

Novel treatment strategies for myeloproliferative neoplasms.

Rinsho Ketsueki 2019 ;60(9):1176-1185

Department of Leukemia, MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.1176DOI Listing
January 2019

Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.

Br J Haematol 2018 12 19;183(5):831-835. Epub 2017 Dec 19.

Department of Stem Cell Transplantation and Cellular Therapy, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15059DOI Listing
December 2018

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.

Ann Hematol 2018 Nov 27;97(11):2071-2080. Epub 2018 Jun 27.

Department of Leukemia, UT MD Anderson Cancer Center, 1515 Holcombe Blvd (Unit 428), Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3402-x
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3402-xDOI Listing
November 2018

A multimodality work-up of patients with Hypereosinophilia.

Am J Hematol 2018 11 26;93(11):1337-1346. Epub 2018 Sep 26.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25247DOI Listing
November 2018

Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere.

J Clin Oncol 2018 Oct 22:JCO2018793497. Epub 2018 Oct 22.

Lucia Masarova and Srdan Verstovsek, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.79.3497
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.79.3497DOI Listing
October 2018

Kit Mutations: New Insights and Diagnostic Value.

Immunol Allergy Clin North Am 2018 08 9;38(3):411-428. Epub 2018 Jun 9.

Leukemia Department, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.iac.2018.04.005DOI Listing
August 2018

Patient Perceptions in Mast Cell Disorders.

Immunol Allergy Clin North Am 2018 08;38(3):505-525

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Mastocytosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898561183003
Publisher Site
http://dx.doi.org/10.1016/j.iac.2018.04.006DOI Listing
August 2018

Management of Myelofibrosis-Related Cytopenias.

Curr Hematol Malig Rep 2018 06;13(3):164-172

Department of Leukemia, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, FC4.3062, Unit 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0447-9DOI Listing
June 2018

Bone marrow findings in blast phase of polycythemia vera.

Ann Hematol 2018 Mar 28;97(3):425-434. Epub 2017 Dec 28.

Department of Hematopathology, Unit 0072, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3211-7DOI Listing
March 2018

Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: commentary.

Authors:
Srdan Verstovsek

Clin Adv Hematol Oncol 2018 Feb;16 Suppl 4(2):20-23

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
February 2018

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Ann Hematol 2018 Jan 15;97(1):109-121. Epub 2017 Nov 15.

Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, 1400 Holcombe Blvd, Unit 428, PO Box 301439, Houston, TX, 77230-1439, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3165-9DOI Listing
January 2018

SOHO State-of-the-Art Update and Next Questions: MPN.

Clin Lymphoma Myeloma Leuk 2018 01;18(1):1-12

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915302PMC
January 2018

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Clin Case Rep 2018 01 6;6(1):155-161. Epub 2017 Dec 6.

Department of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771935PMC
January 2018

Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

Curr Hematol Malig Rep 2017 12;12(6):507-509

Leukemia Department, MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-017-0423-9
Publisher Site
http://dx.doi.org/10.1007/s11899-017-0423-9DOI Listing
December 2017

JAK2 detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.

Leuk Res 2017 12 31;63:53-55. Epub 2017 Oct 31.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.10.016DOI Listing
December 2017

Targeting cistrome and dysregulated transcriptome of post-MPN sAML.

Oncotarget 2017 Nov 11;8(55):93301-93302. Epub 2017 Oct 11.

Kapil N. Bhalla: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21752DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706789PMC
November 2017

Ruxolitinib for essential thrombocythemia?

Oncoscience 2017 Nov 1;4(11-12):148-149. Epub 2017 Nov 1.

Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769968PMC
November 2017

Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis.

Leuk Lymphoma 2017 10 28;58(10):2508-2510. Epub 2017 Feb 28.

f Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1295147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489356PMC
October 2017

Immunotherapy based approaches in myelofibrosis.

Expert Rev Hematol 2017 10 22;10(10):903-914. Epub 2017 Aug 22.

a MD Anderson Cancer Center , The University of Texas , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1366853DOI Listing
October 2017

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Ann Hematol 2017 Oct 14;96(10):1595-1604. Epub 2017 Aug 14.

Department of Leukemia, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd., Box 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3099-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693670PMC
October 2017

A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Leuk Res 2017 10 31;61:89-95. Epub 2017 Aug 31.

University of Utah School of Medicine, Division of Hematology, 30 North 1900 East, Salt Lake City, UT 84132, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.08.010DOI Listing
October 2017

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Leuk Res 2017 09 30;60:11-17. Epub 2017 May 30.

Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.05.002DOI Listing
September 2017

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.

Leuk Res 2017 08 1;59:105-109. Epub 2017 Jun 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.05.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573652PMC
August 2017

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Leuk Res 2017 08 2;59:110-116. Epub 2017 Jun 2.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573611PMC
August 2017

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Clin Lymphoma Myeloma Leuk 2017 08 12;17(8):479-487. Epub 2017 May 12.

Division of Cancer Medicine, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.05.015DOI Listing
August 2017

3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Mod Pathol 2017 07 24;30(7):940-951. Epub 2017 Mar 24.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2017.19DOI Listing
July 2017

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Blood 2017 07 12;130(2):115-125. Epub 2017 May 12.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-04-742288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510786PMC
July 2017

Developmental Therapeutics in Myeloproliferative Neoplasms.

Clin Lymphoma Myeloma Leuk 2017 07;17S:S43-S52

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650173021
Publisher Site
http://dx.doi.org/10.1016/j.clml.2017.02.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540010PMC
July 2017

Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance.

Leuk Res 2017 06 8;57:85-88. Epub 2017 Mar 8.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.03.006DOI Listing
June 2017

Investigational Janus kinase inhibitors in development for myelofibrosis.

Expert Opin Investig Drugs 2017 Jun 8;26(6):723-734. Epub 2017 May 8.

a Department of Leukemia , University of TX MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1323871DOI Listing
June 2017

Therapy-related myelofibrosis does not appear to exist.

Blood Adv 2017 Jun 26;1(14):863-866. Epub 2017 May 26.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017007369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737601PMC
June 2017

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

Leuk Res 2017 05 31;56:52-59. Epub 2017 Jan 31.

CRIMM-Center of Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi and University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.01.032DOI Listing
May 2017

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.

Ann Hematol 2017 May 28;96(5):733-738. Epub 2017 Feb 28.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-2956-3DOI Listing
May 2017

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.

Curr Opin Hematol 2017 03;24(2):115-124

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000320DOI Listing
March 2017

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.

Br J Haematol 2017 Mar 21;176(6):939-949. Epub 2017 Feb 21.

Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14501DOI Listing
March 2017

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis.

Blood Res 2017 Mar 27;52(1):71-73. Epub 2017 Mar 27.

Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5045/br.2017.52.1.71DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383595PMC
March 2017